Healthy volunteers help pick best pill form for new drug
NCT ID NCT07240116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolled 18 healthy adults to compare how the body absorbs miricorilant from different tablet types. Participants received the drug in various forms and doses on separate days. The goal is to find which formulation works best for future trials. This is an early-stage study focused on drug behavior, not treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Miricorilant
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
18 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Able to understand written informed consent * Willing and able to comply with study requirements * Willing to comply with protocol-specified contraception requirements * Healthy male or non-pregnant, non-lactating female of non-childbearing potential per Investigator assessment. * Body mass index (BMI) of 18.0 to 30.0 kg/m\^2 at screening * Weight of at least 50 kg at screening Exclusion Criteria: * Serious adverse reaction or hypersensitivity to any drug or formulation excipients * History of clinically significant allergy requiring treatment * History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder * Any form of cancer within the 5 years before the first does of this study * History and/or symptoms of adrenal insufficiency * History of clinically significant GI disease * Condition or history of a condition that could be aggravated by glucocorticoid antagonism or glucocorticoid activation * History of additional risk factors for torsades de pointes * Poor venous access that limits phlebotomy * Clinically significant abnormal clinical chemistry, hematology or urinalysis * History or evidence of hypokalemia * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results * Evidence of renal impairment at screening * Positive serum or highly sensitive urine pregnancy test at screening or first admission * Clinically significant ECG abnormalities or vital sign abnormalities at screening or baseline * Received any investigational medicinal products (IMP) in a clinical research study within 5 half-lives or within 30 days prior to first dose * Donation of blood within 2 months or donation of plasma within 1 week prior to first dose of study medication * Are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies in the 14 days before first IMP administration * Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months before first IMP administration or 3 months for inhaled products * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption as defined in the study protocol * A confirmed positive alcohol urine test at screening or first admission * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * A confirmed positive urine cotinine test at screening or first admission * Positive drug screen test result at screening or first admission * Male subjects with pregnant or lactating partners * Study site or Sponsor employee or immediate family members one * Failure to satisfy the Investigator of fitness to participate for any other reason.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site 01
Miami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chewable postbiotic tablet keep plaque and gum inflammation at bay?
- Can a new oral drug safely help older adults manage weight?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others